spacer
home > ebr > current issue
PUBLICATIONS

European Biopharmaceutical Review

ebr
Autumn 2014

   
Text
PDF
Editor’s Letter

Deborah O’Neil ponders the recent Ebola outbreak and discusses some of this edition’s focus features.
 
view
download pdf
Science and Innovation
Mass Spectrometry

Molecular Weight


Intact mass analysis has the benefits of minimal sample preparation, high-speed analysis and minor method-induced modifications. Nicholas Michael and Pat Easton at Reading Scientific Services Ltd explain.
 
view
download pdf
Column Technology

HPLC’s Golden Jubilee: Part 2


In the second of a two-part series, Ronald Majors from Agilent Technologies reviews the progress of highperformance liquid chromatography over the last 50 years and considers what the future holds.
 
view
download pdf
bullet
BioResearch and Innovation
Nanotechnology

On Target


A sound understanding of biological responses, combined with close coordination of drug delivery mechanisms and particle toxicology, are essential for the safe and effective use of nanoparticles in drug delivery, advises Aiswariya Chidambaram at Frost & Sullivan.
 
view
download pdf
BioDevelopment
Transient Gene Expression

Shifting the Balance

Stable cell line generation can be costly in terms of time, labour and money. Karen Donato, Krista Steger and Meg Duskin at MaxCyte, Inc weigh up transient gene expression as an alternative.
 
view
download pdf
Q&A: Cell Line Development

Path to Progress


FUJIFILM Diosynth Biotechnologies’ Alison Porter tells EBR what must be considered when creating a new host cell line, and gives tips on how to save future development time and meet production requirements.



 
view
download pdf
Mammalian Cell Culture

Testing Times


Universitat Autònoma de Barcelona’s Francesc Gòdia recommends the design of experiments approach as a means to accelerate the screening of effi cient compounds and the corresponding optimal conditions.
 
view
download pdf
bullet
Legal, Regulatory and Public Policy
Regulatory Challenge

Rapid response


The growing advances in genomics and how this area fi ts in with personalised medicine is uncharted territory, particularly for regulatory agencies. Regina Au at BioMarketing Insight contemplates the current approval processes.


 
view
download pdf
Personalised Medicine

Individual Focus

With molecular profi ling allowing for patient-specific therapeutic strategies, the need to encourage research must be balanced against demands for privacy protection, reports Emma Naks at EBR.
 
view
download pdf
EU Legislation

In Harmony?


Shuna Mason from CMS points out that although recent legislative changes reveal an intention to promote personalised medicine within the EU, there is still some way to go in harmonising regulation.
 
view
download pdf
bullet
BioDevelopment and Regulatory
Temperature Standardisation

Playing it Cool


Rolf Ehrhardt and Maria Thompson from BioCision raise awareness of the importance of temperature standardisation in the field of cell biology, and evaluate current practice.
 
view
download pdf
bullet
INTERVIEW
Industry Insight

Hot Spot


EBR talks to Frédéric Druck at BioWin about Wallonia, Belgium, and why this region is proving a favourite for companies looking to focus on immunology R&D.
 
view
download pdf
bullet
INDUSTRY DYNAMICS
In Brief

A Tale of Two Cities


Despite their common heritage, the US and UK have evolved two distinct approaches to the provision of healthcare and managing costs on a national scale. Emile Bellot explores further.
 
view
download pdf
bullet
BUSINESS STRATEGY
Industry Collaboration

Better Together


Pharma companies must realise that productivity does not exist only in delivering effective new compounds, but also in playing a responsive and active part alongside others, reason Peter Wagner and Christoph Schnorr of Quintiles.


 
view
download pdf
Open Innovation

Compound Interest


Simon MacKenzie and Sylviane Boucharens at BioAscent Discovery Ltd suggest why using corporate compound collections as a shareable asset is both promising and valuable.
 
view
download pdf
Clinical Supply Partnerships

Need for Speed

Martin Lamb and Claudia Williams at Biotec Services International propose partnering with a clinical supply business to help cut costs and reduce time to market.
 
view
download pdf
bullet
BIOIMAGING
Drug Development

Eye for Success


MPI Research’s Scott Haller believes that contemporary molecular imaging offers pharma a set of tools capable of dramatically de-risking clinical drug development.
 
view
download pdf
Kinetic Modelling

Made to Measure


When it comes to oncology imaging, volumes can allow for a more complete picture, as well as a sophisticated estimation of tumour growth. David Raunig, Gregory Goldmacher and Stephanie Owens at ICON reflect.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Freight savings from thinner, lighter cargo covers

With more and more airlines using 'dimensional' or 'volume' weight rather than 'actual weight' to calculate fuel and other surcharges, shippers are looking to trim both the weight and bulk of their freight packaging. 
More info >>

White Papers

Technology Solutions - Driving efficiencies, quality and operational excellence

Worldwide Clinical Trials Ltd

Clinical trials involve the entry, analysis and reporting of millions of pieces of data; year-on-year, the amount of data required to manage efficacy and safety increases exponentially. Recently, solutions available to support this activity have grown in numbers and complexity. The rise of Tablets and Smart Phones combined with the growth of Cloud or SAS solutions has resulted in the technology landscape required to support complex, global studies becoming more confusing.
More info >>

Industry Events

Clinical Trials in CNS

11-12 November 2014, Marriott Regents Park Hotel, London, UK

SMi is delighted to announce its 13th annual Clinical Trials in CNS Conference. With an ever increasing average life expectancy, neurodegenerative diseases are becoming more prevalent in society.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement